Is Quniagolide safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Quniagolide. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Quinagolide is not approved for marketing in the US by the US Food and Drug Administration. It is selective dopamine D2 receptor that reduces serum prolactin. Quinagolide is usually not used during breastfeeding because it suppresses lactation. No published information was found on the use of quinagolide in nursing mothers.
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
A small preliminary study compared quinagolide (CV 205-502) to bromocriptine for 21 days starting in the first day postpartum in mothers who did not wish to breastfeed. Serum prolactin normalized more rapidly with bromocriptine and more women had breast symptoms with quinagolide. Efficacy in suppressing lactation was similar between the groups.[1]
Levels in milk
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Quniagolide” (quinagolide). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.